We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-2.95%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.13B
AUM Growth
-$333M
Cap. Flow
-$249M
Cap. Flow %
-22.11%
Top 10 Hldgs %
64.02%
Holding
82
New
15
Increased
14
Reduced
31
Closed
17
Avg Time Held Equity + Options
1.7 years
Top 10 Avg Time Held Equity + Options
1.2 years
Top 20 Avg Time Held Equity + Options
1.3 years
Avg Time Held Equity only
1.8 years
Top 10 Avg Time Held Equity only
1.1 years
Top 20 Avg Time Held Equity only
1.3 years

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$16.3M
2
BRKR icon
Bruker
BRKR
+$13.9M
3
TFX icon
Teleflex
TFX
+$12.7M
4
PCVX icon
Vaxcyte
PCVX
+$12.7M
5
EW icon
Edwards Lifesciences
EW
+$11.9M

Top Sells

Rank Stock Value
1
INSM icon
Insmed
INSM
+$79.5M
2
SNDX icon
Syndax Pharmaceuticals
SNDX
+$64.4M
3
UTHR icon
United Therapeutics
UTHR
+$32.1M
4
TECH icon
Bio-Techne
TECH
+$26.7M
5
CYH icon
Community Health Systems
CYH
+$25M

Sector Composition

Rank Sector Weight
1 Healthcare 86.03%
2 Miscellaneous 13.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MRVI icon
76
Maravai LifeSciences
MRVI
$1.02B
– –
-336,966
Closed -$2.8M –
STAA icon
77
STAAR Surgical
STAA
$1.06B
– –
-91,199
Closed -$3.39M –
STOK icon
78
Stoke Therapeutics
STOK
$1.56B
– –
-52,006
Closed -$639K –
TRML icon
79
DELISTED
Tourmaline Bio
TRML
– –
-84,380
Closed -$2.17M –
FNA icon
80
DELISTED
Paragon 28, Inc.
FNA
– –
-749,213
Closed -$5M –
NVRO icon
81
DELISTED
NEVRO CORP.
NVRO
– –
-313,780
Closed -$1.75M –
ITCI icon
82
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-124,491
Closed -$9.11M –
1 2 3
4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q4 2024 Portfolio in Review

As of Q4 2024, Eversept Partners held 82 positions worth $1.13B, down 23% from $1.46B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Eversept Partners withdrew a net $249M in Q4 2024, closing 17 positions and reducing 31 holdings. Its most notable exit was Insmed, an estimated $79.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, down from 89% a quarter earlier, followed by Miscellaneous.

Against the trend, Eversept Partners opened a new position in Bruker worth $13.8M.

  • Eversept Partners's largest Q4 2024 buy was Bruker: 234,934 shares worth $13.8M.
  • Eversept Partners added most to HCA Healthcare in Q4 2024, an estimated $16.3M increase.
  • Eversept Partners's biggest Q4 2024 reduction was Syndax Pharmaceuticals, cutting an estimated $64.4M.
  • Eversept Partners fully exited Insmed in Q4 2024, selling an estimated $79.5M.
  • Eversept Partners's ten largest holdings make up 64% of its $1.13B portfolio in Q4 2024.
  • Eversept Partners opened 15 new positions and closed 17 in Q4 2024.
  • Eversept Partners's portfolio value fell 23% quarter-over-quarter to $1.13B.

Based on Eversept Partners's 13F filing for Q4 2024, filed 14 Feb 2025.